hd21
페이지 정보
본문
Allis Chalmers HD21 - Starting and working
A 1958 Allis Chalmers HD21A
@jerryhammack1318 : I remember my great uncle Clifford Sloan hauling these to a mine in the early to mid 70s . He was the only heavy equipment hauler in the area at the time. He ran a cab over Peterbuilt . When he got his rig repainted the paintshop screwed him he was colorblind. It was supposed to have been blue. They painted it bright purple. He got so many good comments on that rig he kept the purple! He was well-known over the road ! You couldn't miss seeing that big bright purple Peterbuilt! Hauling huge loads allover the south west! Miss those hd 21s and that purple Pete! Bless you uncle Frank ! R.i.p.
@Buzzbox3rd : Love the sound of an AC engine. Great vid.
@joshtaylor4249 : I love old iron. Even though new machines are more user friendly and comfortable, they will never have the style and longevity of old equipment.. That Allis Chalmers could sit for 15 years untouched.. New batts, and a whiff of either. Shes working again.. Beautiful..
@RJ-lj3zt : A great dozer doing a great job!
Allis Chalmers
@valdemarantoniodossantos3167 : Ai é maquina dê verdade companheiro tenho 2 hD 6
Findings from the HD21 trial: safety profile of the BrECADD regimen in HL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, summarizes the aims and findings of the HD21 (NCT02661503) trial which compared the safety profile of the novel BrECADD regimen (brentuximab vedotin, etoposide, doxorubicin, cyclophosphamide, dacarbazine, and dexamethasone) to the escalated BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). Prof. Borchmann explains that BrECADD was found to be superior to BEACOPP in terms of showing improved treatment-related mortality, lower neuropathy, and fewer transfusions. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Updates from the HD21 study: escalated BEACOPP vs BrECADD for the treatment of HL
In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the HD21 trial (NCT02661503), a highly anticipated clinical trial comparing the use of escalated BEACOPP with BrECADD in patients with classical Hodgkin lymphoma (HL). Dr Collins first discusses the differences between the BEACOPP and BrECADD protocols, and further explains the main aim of this study, which is to investigate whether BrECADD is less toxic than the commonly used escalated BEACOPP approach. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
A 1958 Allis Chalmers HD21A
@jerryhammack1318 : I remember my great uncle Clifford Sloan hauling these to a mine in the early to mid 70s . He was the only heavy equipment hauler in the area at the time. He ran a cab over Peterbuilt . When he got his rig repainted the paintshop screwed him he was colorblind. It was supposed to have been blue. They painted it bright purple. He got so many good comments on that rig he kept the purple! He was well-known over the road ! You couldn't miss seeing that big bright purple Peterbuilt! Hauling huge loads allover the south west! Miss those hd 21s and that purple Pete! Bless you uncle Frank ! R.i.p.
@Buzzbox3rd : Love the sound of an AC engine. Great vid.
@joshtaylor4249 : I love old iron. Even though new machines are more user friendly and comfortable, they will never have the style and longevity of old equipment.. That Allis Chalmers could sit for 15 years untouched.. New batts, and a whiff of either. Shes working again.. Beautiful..
@RJ-lj3zt : A great dozer doing a great job!
Allis Chalmers
@valdemarantoniodossantos3167 : Ai é maquina dê verdade companheiro tenho 2 hD 6
Findings from the HD21 trial: safety profile of the BrECADD regimen in HL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, summarizes the aims and findings of the HD21 (NCT02661503) trial which compared the safety profile of the novel BrECADD regimen (brentuximab vedotin, etoposide, doxorubicin, cyclophosphamide, dacarbazine, and dexamethasone) to the escalated BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). Prof. Borchmann explains that BrECADD was found to be superior to BEACOPP in terms of showing improved treatment-related mortality, lower neuropathy, and fewer transfusions. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Updates from the HD21 study: escalated BEACOPP vs BrECADD for the treatment of HL
In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the HD21 trial (NCT02661503), a highly anticipated clinical trial comparing the use of escalated BEACOPP with BrECADD in patients with classical Hodgkin lymphoma (HL). Dr Collins first discusses the differences between the BEACOPP and BrECADD protocols, and further explains the main aim of this study, which is to investigate whether BrECADD is less toxic than the commonly used escalated BEACOPP approach. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
... 
댓글목록
등록된 댓글이 없습니다.
